RAPT Therapeutics Zukünftiges Wachstum

Future Kriterienprüfungen 0/6

RAPT TherapeuticsDer Gewinn des Unternehmens wird voraussichtlich um 5.5% pro Jahr sinken, während der Jahresumsatz voraussichtlich um 62.4% pro Jahr wachsen wird. Der Gewinn pro Aktie wird voraussichtlich sinken um 1% pro Jahr. Die Eigenkapitalrendite wird in 3 Jahren voraussichtlich -70.3% betragen.

Wichtige Informationen

-7.4%

Wachstumsrate der Gewinne

-1.2%

EPS-Wachstumsrate

Biotechs Gewinnwachstum	28.4%
Wachstumsrate der Einnahmen	71.0%
Zukünftige Eigenkapitalrendite	-73.0%
Analystenabdeckung	Good
Zuletzt aktualisiert	06 Sep 2024

Jüngste Aktualisierungen zum künftigen Wachstum

Recent updates

RAPT: CCR4 Inhibition Presses On For Now With Oncology Focus

Jul 24

Companies Like RAPT Therapeutics (NASDAQ:RAPT) Could Be Quite Risky

Jun 13

RAPT Therapeutics: Dip Following FDA Clinical Hold Creates Asymmetric Opportunity

May 20

RAPT Therapeutics (NASDAQ:RAPT) Is In A Good Position To Deliver On Growth Plans

Jan 25

RAPT Therapeutics (NASDAQ:RAPT) Is In A Good Position To Deliver On Growth Plans

Oct 15

RAPT Therapeutics (RAPT) skyrockets 100% on positive RPT193 data in early-stage atopic dermatitis study

Jun 14

RAPT Therapeutics (NASDAQ:RAPT) Is In A Good Position To Deliver On Growth Plans

Jun 08

Should You Take Comfort From Insider Transactions At RAPT Therapeutics, Inc. (NASDAQ:RAPT)?

Mar 15

We Think RAPT Therapeutics (NASDAQ:RAPT) Can Easily Afford To Drive Business Growth

Feb 15

RAPT Therapeutics' (NASDAQ:RAPT) Stock Price Has Reduced 56% In The Past Year

Jan 18

RAPT Therapeutics: Interesting Asset, But Doubtful History And Bad Market Reaction

Jan 08

Here's What RAPT Therapeutics, Inc.'s (NASDAQ:RAPT) Shareholder Ownership Structure Looks Like

Dec 21

The Independent Chairman of the Board of RAPT Therapeutics, Inc. (NASDAQ:RAPT), William Rieflin, Just Bought 12% More Shares

Nov 23

Earnings Beat: RAPT Therapeutics, Inc. (NASDAQ:RAPT) Just Beat Analyst Forecasts, And Analysts Have Been Lifting Their Forecasts

Nov 19

RAPT Therapeutics tumbles 25% despite promising FLX475 data in multiple cancers

Nov 16

Gewinn- und Umsatzwachstumsprognosen

NasdaqGM:RAPT - Zukünftige Analystenschätzungen und Finanzdaten der Vergangenheit (USD Millions)
Datum	Umsatz	Gewinne	Freier Cashflow	Bargeld aus operativen Tätigkeiten	Durchschn. Anz. Analysten
12/31/2026	16	-219	-163	-88	3
12/31/2025	N/A	-114	-119	-108	8
12/31/2024	N/A	-105	-92	-73	8
6/30/2024	N/A	-120	-105	-105	N/A
3/31/2024	N/A	-118	-106	-106	N/A
12/31/2023	N/A	-117	-98	-97	N/A
9/30/2023	N/A	-109	-93	-92	N/A
6/30/2023	N/A	-99	-89	-87	N/A
3/31/2023	1	-93	-75	-74	N/A
12/31/2022	2	-84	-72	-71	N/A
9/30/2022	2	-79	-70	-69	N/A
6/30/2022	3	-76	-65	-64	N/A
3/31/2022	3	-73	-63	-63	N/A
12/31/2021	4	-69	-62	-61	N/A
9/30/2021	4	-64	-56	-56	N/A
6/30/2021	5	-60	-54	-53	N/A
3/31/2021	5	-56	-46	-46	N/A
12/31/2020	5	-53	-41	-40	N/A
9/30/2020	4	-53	-31	-31	N/A
6/30/2020	2	-49	-33	-33	N/A
3/31/2020	1	-47	-36	-36	N/A
12/31/2019	N/A	-43	-36	-35	N/A
9/30/2019	N/A	-39	-42	-39	N/A
6/30/2019	N/A	-40	-39	-36	N/A
3/31/2019	N/A	-37	-37	-34	N/A
12/31/2018	N/A	-36	-36	-33	N/A

Analystenprognosen zum zukünftigen Wachstum

Einkommen vs. Sparrate: RAPT wird in den nächsten 3 Jahren voraussichtlich unrentabel bleiben.

Ertrag vs. Markt: RAPT wird in den nächsten 3 Jahren voraussichtlich unrentabel bleiben.

Hohe Wachstumserträge: RAPT wird in den nächsten 3 Jahren voraussichtlich unrentabel bleiben.

Einnahmen vs. Markt: RAPT wird im nächsten Jahr voraussichtlich keine Einnahmen haben.

Hohe Wachstumseinnahmen: RAPT wird im nächsten Jahr voraussichtlich keine Einnahmen haben.

Wachstumsprognosen für den Gewinn je Aktie

Künftige Eigenkapitalrendite

Künftige Eigenkapitalrendite: RAPT wird voraussichtlich in 3 Jahren unrentabel sein.

RAPT Therapeutics Zukünftiges Wachstum

Future Kriterienprüfungen 0/6

Wichtige Informationen

Jüngste Aktualisierungen zum künftigen Wachstum

Price target decreased by 18% to US$18.14

Price target decreased by 21% to US$33.63

Consensus forecasts updated

Consensus forecasts updated

Consensus forecasts updated

Price target decreased to US$50.29

Recent updates

Rapt Therapeutics Approves Reduction to Their Workforce

RAPT: CCR4 Inhibition Presses On For Now With Oncology Focus

Companies Like RAPT Therapeutics (NASDAQ:RAPT) Could Be Quite Risky

RAPT Therapeutics: Dip Following FDA Clinical Hold Creates Asymmetric Opportunity

Price target decreased by 18% to US$18.14

RAPT Therapeutics Announces Promising Results from Phase 2 Trial of Tivumecirnon in Combination with Anti-PD-1 Immunotherapy in CPI-Experienced Head and Neck Cancer Patients

RAPT Therapeutics, Inc., Annual General Meeting, May 22, 2024

New minor risk - Shareholder dilution

Price target decreased by 21% to US$33.63

Is RAPT Therapeutics (NASDAQ:RAPT) In A Good Position To Invest In Growth?

RAPT Therapeutics, Inc. Announces FDA Verbally Notifies Clinical Hold on its Phase 2b Trial of Zelnecirnon (RPT193) in Atopic Dermatitis and its Phase 2a Trial in Asthma

New major risk - Revenue and earnings growth

RAPT Therapeutics, Inc. Appoints Nipun Davar as Senior Vice President of Technical Operations

RAPT Therapeutics, Inc. Announces Publication of Phase 1a/1b Clinical Trial of Zelnecirnon (RPT193) to Treat Atopic Dermatitis in Allergy

RAPT Therapeutics, Inc. Announces Publication of Phase 1a/1b Clinical Trial of Zelnecirnon (RPT193) to Treat Atopic Dermatitis in Allergy

New major risk - Revenue and earnings growth

New minor risk - Share price stability

RAPT Therapeutics, Inc. Announces Positive Data, Including Objective Response Rates and Progression-Free Survival, from its Phase 2 Trial of FLX475 in Combination with a Checkpoint Inhibitor in Patients with Advanced NSCLC

New major risk - Revenue and earnings growth

We Think RAPT Therapeutics (NASDAQ:RAPT) Can Afford To Drive Business Growth

First quarter 2023 earnings released: US$0.77 loss per share (vs US$0.69 loss in 1Q 2022)

We Think RAPT Therapeutics (NASDAQ:RAPT) Can Afford To Drive Business Growth

Chief Medical Officer notifies of intention to sell stock

Insider recently bought US$98k worth of stock

Full year 2022 earnings: EPS in line with expectations, revenues disappoint

Chief Medical Officer notifies of intention to sell stock

We're Hopeful That RAPT Therapeutics (NASDAQ:RAPT) Will Use Its Cash Wisely

Chief Medical Officer notifies of intention to sell stock

Chief Medical Officer notifies of intention to sell stock

Insufficient new directors

RAPT Therapeutics Presents Update from its Phase 1/2 Clinical Trial for FLX475 as Monotherapy and in Combination with Pembrolizumab in Patients with Advanced Cancer

Chief Medical Officer notifies of intention to sell stock

Consensus forecasts updated

Third quarter 2022 earnings released: US$0.63 loss per share (vs US$0.63 loss in 3Q 2021)

Third quarter 2022 earnings released: US$0.63 loss per share (vs US$0.63 loss in 3Q 2021)

Chief Medical Officer notifies of intention to sell stock

We're Hopeful That RAPT Therapeutics (NASDAQ:RAPT) Will Use Its Cash Wisely

RAPT Therapeutics Announces Executive Changes

Consensus forecasts updated

Consensus forecasts updated

Second quarter 2022 earnings: EPS and revenues exceed analyst expectations

Price target decreased to US$50.29

RAPT Therapeutics, Inc. announced that it expects to receive $49.9996 million in funding from Redmile Group, LLC

Price target decreased to US$53.00

RAPT Therapeutics Announces Initiation of Phase 2B Trial of Rpt193 in Patients with Moderate-To-Severe Atopic Dermatitis

Consensus forecasts updated

First quarter 2022 earnings: Revenues exceed analysts expectations while EPS lags behind

Insider recently bought US$77k worth of stock

RAPT Therapeutics, Inc. Announces Appointment of Gwen Carscadden as Chief Human Resources Officer

RAPT Therapeutics, Inc., Annual General Meeting, May 25, 2022

Consensus forecasts updated

Consensus forecasts updated

RAPT Therapeutics Announces Biomarker Data from Phase 1b Trial of RPT193 Consistent with Disease Modification in Atopic Dermatitis

Full year 2021 earnings: Revenues exceed analysts expectations while EPS lags behind

RAPT Therapeutics (NASDAQ:RAPT) Is In A Good Position To Deliver On Growth Plans

Chief Scientific Officer exercised options and sold US$69k worth of stock

Chief Scientific Officer exercised options and sold US$65k worth of stock

Third quarter 2021 earnings released: US$0.63 loss per share (vs US$0.60 loss in 3Q 2020)

RAPT Therapeutics (NASDAQ:RAPT) Is In A Good Position To Deliver On Growth Plans

Chief Scientific Officer exercised options and sold US$65k worth of stock

Insider recently sold US$424k worth of stock

Chief Scientific Officer exercised options and sold US$78k worth of stock

Price target increased to US$62.14

Member of Scientific Advisory Board recently sold US$1.2m worth of stock

Insider recently sold US$1.1m worth of stock

Chief Scientific Officer exercised options and sold US$66k worth of stock

Second quarter 2021 earnings released: US$0.63 loss per share (vs US$0.51 loss in 2Q 2020)

Consensus forecasts updated

Chief Medical Officer exercised options to buy US$256k worth of stock.